PDF(Pubmed)
Abstract：
We are witnessing the revival of the CAM model, which has already used been in the past by several researchers studying angiogenesis and anti-cancer drugs and now offers a refined model to fill, in the translational meaning, the gap between in vitro and in vivo studies. It can be used for a wide range of purposes, from testing cytotoxicity, pharmacokinetics, tumorigenesis, and invasion to the action mechanisms of molecules and validation of new materials from tissue engineering research. The CAM model is easy to use, with a fast outcome, and makes experimental research more sustainable since it allows us to replace, reduce, and refine pre-clinical experimentation (\"3Rs\" rules). This review aims to highlight some unique potential that the CAM-assay presents; in particular, the authors intend to use the CAM model in the future to verify, in a microenvironment comparable to in vivo conditions, albeit simplified, the angiogenic ability of functionalized 3D constructs to be used in regenerative medicine strategies in the recovery of skeletal injuries of critical size (CSD) that do not repair spontaneously. For this purpose, organotypic cultures will be planned on several CAMs set up in temporal sequences, and a sort of organ model for assessing CSD will be utilized in the CAM bioreactor rather than in vivo.
摘要：
我们正在见证CAM模型的复兴，一些研究血管生成和抗癌药物的研究人员过去已经使用过，现在提供了一个完善的模型来填充，在翻译意义上，体外和体内研究之间的差距。它可以用于广泛的目的，通过测试细胞毒性，药代动力学，肿瘤发生，分子的作用机制和组织工程研究新材料的验证。CAM模型易于使用，结果很快，并使实验研究更具可持续性，因为它允许我们替代，reduce,并完善临床前实验(“3Rs”规则)。这篇综述旨在强调CAM测定法呈现的一些独特潜力；特别是，作者打算在未来使用CAM模型进行验证，在与体内条件相当的微环境中，尽管简化了，功能化3D构建体的血管生成能力，可用于再生医学策略，以恢复无法自发修复的临界大小的骨骼损伤（CSD）。为此,器官型培养将计划在按时间序列设置的几个CAM上进行，和一种用于评估CSD的器官模型将用于CAM生物反应器而不是体内。
